2024
Incorporating transgender and nonbinary participants in phase 1 clinical drug trials: Current knowledge gaps and considerations. (Journal article)
Walker, L. E., Stackpoole, M., Hodge, D., & FitzGerald, R. (2024). Incorporating transgender and nonbinary participants in phase 1 clinical drug trials: Current knowledge gaps and considerations.. British journal of clinical pharmacology. doi:10.1111/bcp.16073DOI: 10.1111/bcp.16073
2023
Granana-Castillo, S., Williams, A., Pham, T., Khoo, S., Hodge, D., Akpan, A., . . . Siccardi, M. (2023). General Framework to Quantitatively Predict Pharmacokinetic Induction Drug-Drug Interactions Using In Vitro Data. CLINICAL PHARMACOKINETICS, 62(5), 737-748. doi:10.1007/s40262-023-01229-3DOI: 10.1007/s40262-023-01229-3
Prevalence of Potentially Clinically Significant Drug-Drug Interactions With Antiretrovirals Against HIV Over Three Decades: A Systematic Review of the Literature (Journal article)
Hodge, D., Hodel, E. M., Hughes, E., Hazenberg, P., Granana Castillo, S., Gibbons, S., . . . Khoo, S. (2023). Prevalence of Potentially Clinically Significant Drug-Drug Interactions With Antiretrovirals Against HIV Over Three Decades: A Systematic Review of the Literature. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 92(2), 97-105. doi:10.1097/QAI.0000000000003122DOI: 10.1097/QAI.0000000000003122
2022
Requests for drug-drug interaction data on direct-acting antivirals and enzyme inducing anti-epileptic agents: an overview of the HEP Interaction checker database of the University of Liverpool (Journal article)
Burger, D., Back, D., Martin, J., Hodge, D., Van Seyen, M., Chiong, J., . . . Marra, F. (2022). Requests for drug-drug interaction data on direct-acting antivirals and enzyme inducing anti-epileptic agents: an overview of the HEP Interaction checker database of the University of Liverpool. Journal of Hepatology, 77, S580-S581. doi:10.1016/s0168-8278(22)01481-7DOI: 10.1016/s0168-8278(22)01481-7
Drug interactions: a review of the unseen danger of experimental COVID-19 therapies (vol 75, pg 3417, 2020) (Journal article)
Hodge, D., Marra, F., Marzolini, C., Boyle, A., Gibbons, S., Siccardi, M., . . . Khoo, S. (2022). Drug interactions: a review of the unseen danger of experimental COVID-19 therapies (vol 75, pg 3417, 2020). JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 77(7), 2050. doi:10.1093/jac/dkac111DOI: 10.1093/jac/dkac111
Montanha, M. C., Cottura, N., Booth, M., Hodge, D., Bunglawala, F., Kinvig, H., . . . Siccardi, M. (2022). PBPK Modelling of Dexamethasone in Patients With COVID-19 and Liver Disease. FRONTIERS IN PHARMACOLOGY, 13. doi:10.3389/fphar.2022.814134DOI: 10.3389/fphar.2022.814134
2021
Hodge, D., Back, D. J., Gibbons, S., Khoo, S. H., & Marzolini, C. (2021). Pharmacokinetics and Drug-Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine. CLINICAL PHARMACOKINETICS, 60(7), 835-853. doi:10.1007/s40262-021-01005-1DOI: 10.1007/s40262-021-01005-1
Back, D., Marzolini, C., Hodge, C., Marra, F., Boyle, A., Gibbons, S., . . . Khoo, S. (2021). COVID-19 treatment in patients with comorbidities: Awareness of drug-drug interactions. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 87(1), 212-213. doi:10.1111/bcp.14358DOI: 10.1111/bcp.14358
2020
Hodge, D., Marra, F., Marzolini, C., Boyle, A., Gibbons, S., Siccardi, M., . . . Khoo, S. (2020). Drug interactions: a review of the unseen danger of experimental COVID-19 therapies. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75(12), 3417-3424. doi:10.1093/jac/dkaa340DOI: 10.1093/jac/dkaa340
Cellular mechanisms governing glucose-dependent insulinotropic polypeptide secretion (Journal article)
Reimann, F., Diakogiannaki, E., Hodge, D., & Gribble, F. M. (2020). Cellular mechanisms governing glucose-dependent insulinotropic polypeptide secretion. PEPTIDES, 125. doi:10.1016/j.peptides.2019.170206DOI: 10.1016/j.peptides.2019.170206
2019
Boyle, A., Moss, C. E., Marzolini, C., & Khoo, S. (2019). Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine. CLINICAL PHARMACOKINETICS, 58(12), 1553-1565. doi:10.1007/s40262-019-00806-9DOI: 10.1007/s40262-019-00806-9
Chemogenetics defines receptor-mediated functions of short chain free fatty acids (Journal article)
Bolognini, D., Barki, N., Butcher, A. J., Hudson, B. D., Sergeevl, E., Molloy, C., . . . Milligan, G. (2019). Chemogenetics defines receptor-mediated functions of short chain free fatty acids. NATURE CHEMICAL BIOLOGY, 15(5), 489-+. doi:10.1038/s41589-019-0270-1DOI: 10.1038/s41589-019-0270-1
Drug interaction profiles for first line antiretroviral therapy and selected fixed-dose antiretroviral combinations over 20 years of the Liverpool Drug Interaction website (Conference Paper)
Gibbons, S., Marzolini, C., Moss, C., McAllister, K., Chiong, J., Back, D., & Khoo, S. (2019). Drug interaction profiles for first line antiretroviral therapy and selected fixed-dose antiretroviral combinations over 20 years of the Liverpool Drug Interaction website. In HIV MEDICINE Vol. 20 (pp. 44-45). Retrieved from https://www.webofscience.com/
2018
Beazley-Long, N., Hodge, D., Ashby, W. R., Bestall, S. M., Almahasneh, F., Durrant, A. M., . . . Donaldson, L. F. (2018). VEGFR2 promotes central endothelial activation and the spread of pain in inflammatory arthritis. BRAIN BEHAVIOR AND IMMUNITY, 74, 49-67. doi:10.1016/j.bbi.2018.03.012DOI: 10.1016/j.bbi.2018.03.012
2016
A Novel Allosteric Activator of Free Fatty Acid 2 Receptor Displays Unique G<sub>i</sub>-functional Bias (Journal article)
Bolognini, D., Moss, C. E., Nilsson, K., Petersson, A. U., Donnelly, I., Sergeev, E., . . . Milligan, G. (2016). A Novel Allosteric Activator of Free Fatty Acid 2 Receptor Displays Unique G<sub>i</sub>-functional Bias. JOURNAL OF BIOLOGICAL CHEMISTRY, 291(36), 18915-18931. doi:10.1074/jbc.M116.736157DOI: 10.1074/jbc.M116.736157
Lipid derivatives activate GPR119 and trigger GLP-1 secretion in primary murine L-cells (Journal article)
Hodge, D., Glass, L. L., Diakogiannaki, E., Pais, R., Lenaghan, C., Smith, D. M., . . . Reimann, F. (2016). Lipid derivatives activate GPR119 and trigger GLP-1 secretion in primary murine L-cells. PEPTIDES, 77, 16-20. doi:10.1016/j.peptides.2015.06.012DOI: 10.1016/j.peptides.2015.06.012
The Pharmacology and Function of Receptors for Short-Chain Fatty Acids (Journal article)
Bolognini, D., Tobin, A. B., Milligan, G., & Moss, C. E. (2016). The Pharmacology and Function of Receptors for Short-Chain Fatty Acids. MOLECULAR PHARMACOLOGY, 89(3), 388-398. doi:10.1124/mol.115.102301DOI: 10.1124/mol.115.102301
2012
Somatostatin receptor 5 and cannabinoid receptor 1 activation inhibit secretion of glucose-dependent insulinotropic polypeptide from intestinal K cells in rodents (Journal article)
Moss, C. E., Marsh, W. J., Parker, H. E., Ogunnowo-Bada, E., Riches, C. H., Habib, A. M., . . . Reimann, F. (2012). Somatostatin receptor 5 and cannabinoid receptor 1 activation inhibit secretion of glucose-dependent insulinotropic polypeptide from intestinal K cells in rodents. DIABETOLOGIA, 55(11), 3094-3103. doi:10.1007/s00125-012-2663-5DOI: 10.1007/s00125-012-2663-5
Cannabinoid receptor 1 activation inhibits secretion of glucose-dependent insulinotropic polypeptide from intestinal K-cells (Conference Paper)
Moss, C. E., Marsh, W. J., Parker, H. E., Ogunnowo-Bada, E., Riches, C. H., Habib, A. M., . . . Reimann, F. (2012). Cannabinoid receptor 1 activation inhibits secretion of glucose-dependent insulinotropic polypeptide from intestinal K-cells. In DIABETOLOGIA Vol. 55 (pp. S239). Retrieved from https://www.webofscience.com/
2011
Role of phosphodiesterase and adenylate cyclase isozymes in murine colonic glucagon-like peptide 1 secreting cells (Journal article)
Friedlander, R. S., Moss, C. E., Mace, J., Parker, H. E., Tolhurst, G., Habib, A. M., . . . Reimann, F. (2011). Role of phosphodiesterase and adenylate cyclase isozymes in murine colonic glucagon-like peptide 1 secreting cells. BRITISH JOURNAL OF PHARMACOLOGY, 163(2), 261-271. doi:10.1111/j.1476-5381.2010.01107.xDOI: 10.1111/j.1476-5381.2010.01107.x
